Amgen Inc.'s experimental obesity drug, MariTide, led to a weight loss of up to 20% in a yearlong trial involving 592 obese patients, both with and without diabetes. However, the results disappointed investors who expected greater weight loss, causing a decline in the company's shares. Approximately 11% of participants discontinued treatment due to adverse events.